| Participants |
Inclusion criteria
malignant tumour except for haematopoietic malignancy ECOG performance status 0 to 2 20 years old or over at the time of giving informed consent receiving chemotherapy involving cisplatin as first line dose of cisplatin 50 mg/m² over regimens involving standard treatment for vomiting with dexamethasone, aprepitant, and 5‐HT₃ receptor antagonist adequate organ function as defined by (each of the following values are examined within 8 days before entry): AST ≤ 100 IU/L, ALT ≤ 100 IU/L T‐Bill ≤ 2.0 mg/dL CCr ≥ 60 mL/min all subjects must be able to provide written informed consent before entry
Exclusion criteria
known prior severe hypersensitivity to 5‐HT₃ receptor antagonist, corticosteroids, and aprepitant individuals who do not have enough whole body state for antineoplastic agent treatment known symptomatic brain metastasis convulsive disorder that needs anticonvulsant therapy symptom of ascites or pleural effusion that needs puncture obstruction of gastrointestinal tract, for example, gastric outlet or ileus, etc. pregnant, breast‐feeding woman enforced radiotherapy at bottom of diaphragm in the period between 6 days before and 6 days after date of first therapy taking a medicine regularly, for example, 5‐HT₃ receptor antagonists, corticosteroids, antidopamine agonists, phenothiazine tranquilisers,antihistamine drugs, benzodiazepine agents, etc. judged by investigator to be inappropriate for this study
Mean/median age, years: n.r.
Gender: male + female
Tumour/cancer type: solid malignancy (lung cancer, gastric cancer, oesophagus cancer, cervical cancer, endometrial cancer, head and neck cancer, etc.)
Chemotherapy regimen: cisplatin ≥ 50 mg/m²
Country: Japan |
